Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with borderline or locally advanced pancreatic cancer (a specific type called adenocarcinoma), based on recognised medical guidelines
- People whose diagnosis has been confirmed by a tissue or cell sample, ideally taken using a procedure called an endoscopic ultrasound (EUS)
- People whose cancer has not spread to distant parts of the body (no distant spread detected)
- People who are in generally good physical condition and considered well enough to receive chemotherapy and potentially undergo surgery (confirm with trial site)
- People who are willing and able to provide written consent to take part
Who may not be able to join:
- People with other serious health conditions that would make pancreatic surgery or chemotherapy unsafe
- People with known medical reasons why they cannot take the specific drugs used in this trial
- People who are not in good enough physical condition to tolerate treatment (as measured by a standard medical fitness scale)
- People with moderate or severe nerve damage (such as numbness, tingling, or pain in hands or feet)
- People with low white blood cell counts (a type called granulocytes) based on a blood test
- People with low platelet counts based on a blood test
- People with reduced kidney function based on a blood test
- People with low albumin (a protein in the blood) levels
- People with significantly elevated bilirubin levels (a substance related to liver function)
- People with significantly elevated liver enzyme levels based on blood tests
- Women of childbearing age who are not using adequate contraception, or women who are pregnant or breastfeeding
- People with mental or physical conditions that could interfere with their ability to consent or follow the trial plan
- People who have received cancer treatment for pancreatic cancer within the past 5 years
- People who have taken part in another clinical trial involving an experimental treatment in the past 30 days
- People considered by the trial investigators to be unsuitable for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elena Rangelova, PhD, Sahlgrenska University Hospital, Västra Götalandsregion
Phone: +46 31 34 28 216
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival of all BR/LAPC patients; Overall survival of all resected BR/LAPC patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.